----item----
version: 1
id: {DB0F5772-5AC6-4EB7-8280-EC7656607237}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/02/27/US quarterly results roundup
parent: {52387F80-B0CD-4D34-BCBA-94367C9A7458}
name: US quarterly results roundup
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: c4768d98-7ca3-42df-a810-8df70964df46

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 29

US quarterly results round-up
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 5829

<p><pre>Centocor Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months 22.64 30.47 (43.02) (7.02) Year 67.23 75.93 (126.66) (74.38) (ended Dec 31st)</pre><p>Expanding its diagnostics business is one of Centocor's aims for 1995, says the Pennsylvania-based company. Centocor manufactures diagnostic and therapeutic products based on monoclonal antibody and peptide technology.</p><pre>Dynatronics Revenues Net income ($ millions) ($ millions) 1994 1993 1994 1993 3 months 1.48 1.20 0.06 0.01 6 months 3.25 2.39 0.14 0.34 (ended Dec 31st)</pre><p>Dynatronics' president Kelvyn Cullimore says that demand for the company's new 50 series products is strong and adds that total unit sales in the first half of fiscal 1995 were "virtually double last year's volumes". Two additional 50 series products are expected to be introduced in the fourth quarter.</p><pre>Empi Revenues Net income (loss) ($ millions) ($ millions) 1994 1993 1994 1993 3 months 16.43 17.36 (0.39) 2.59 Year 61.30 66.38 3.36 9.33 (ended Dec 31st)</pre><p>A $1.9 million restructuring charge which Empi had announced in December (see Clinica No 634, p 13) resulted in a fourth-quarter net loss. The company expects to launch its Advance Dynamic ROM splint in the US in February. A randomised placebo-controlled clinical study and a protocol optimisation study were recently completed to support reimbursement of Empi's Innova PFS pelvic floor stimulator to treat incontinence in females.</p><pre>Hycor Biomedical Revenues Net income ($ millions) ($ millions) 1994 1993 1994 1993 3 months 6.58 5.85 0.68 0.78 Year 25.90 24.21 2.83 2.28 (ended Dec 31st)</pre><p>Hycor attributes the increase in its fourth-quarter sales to a stronger international allergy business and the inclusion of its latest acquisition, Medical Specialties International. CEO Dr Richard Hamill says that pricing pressure in the US and cost control efforts by laboratory customers on diagnostic product suppliers is reflected in the 1994 results.</p><pre>I-Flow Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 Year 7.00 5.70 (1.60) (2.60) (ended Dec 31st)</pre><p>Infusion-systems manufacturer I-Flow reported its first profitable period in the 1994 fourth-quarter and expects revenues to grow by more than 40% during 1995. I-Flow recently received US FDA permission to market two new products, a mechanical bolus device for patient-controlled analgesia and a mechanical pump for infusing drugs from a standard hospital mini-bag. The two products are expected to be available for marketing in late 1995.</p><pre>InnerDyne Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months 0.53 0.04 (2.22) (2.32) Year 0.88 0.04 (9.90) (10.36) (ended Dec 31st)</pre><p>InnerDyne, based in Sunnyvale, California, resulted from the merger between CardioPulmonics and InnerDyne Medical completed in April 1994. Its fourth-quarter revenues included $230,000 from the sales of the recently introduced Step Access devices for MIS.</p><pre>I-Stat Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months 3.74 1.51 (5.65) (4.39) Year 10.70 4.80 (23.68) (17.08) (ended Dec 31st)</pre><p>I-Stat, a New Jersey-based manufacturer of diagnostic products for blood analysis, introduced blood gas testing capabilities for its I-Stat system during the fourth quarter of 1994. "In response to the initial introduction of our blood gas products, over 10% of the customer base has begun to restructure stat blood analysis around the I-Stat system," says CEO William Moffitt. About 20% of I-Stat's fourth-quarter sales were generated by blood gas products.</p><pre><strong>[C#198601261:Life Technologies]</strong> Revenues Net income ($ millions) ($ millions) 1994 1993 1994 1993 3 months 58.86 51.61 4.54 3.89 Year 235.26 205.62 18.21 16.56 (ended Dec 31st)</pre><p>In 1994, sales of Life Technologies' products other than foetal bovine serum (FBS) increased $25 million compared with the previous year. FBS sales were $5 million higher and represented 18% of total revenue in both 1994 and 1993.</p><pre><strong>[C#198600185:Medtronic]</strong> Revenues Net income ($ millions) ($ millions) 1995 1994 1995 1994 3 months 413.72 334.60 71.38 56.91 9 months 1,225.67 997.96 206.18 165.61 (ended Jan 27th, 1995; Jan 28th, 1994)</pre><p>Medtronic's third-quarter revenues rose 24% in nominal terms compared with a year earlier and 14% when effects of acquisitions and foreign currency translations are excluded. CEO William George stressed the impact of newly-released products and of revenue growth in Europe, Canada and Japan.</p><pre>SangStat Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months 0.22 0.13 (2.51) (1.54) Year 3.67 3.19 (5.55) (3.72) (ended Dec 31st)</pre><p>SangStat, which manufactures therapeutic and monitoring products for organ transplantation, says its 1994 revenues reflect a 30%-rise in product sales and $3 million earned under its collaborative agreement with Baxter Healthcare, compared with $2.6 million in 1993. During the year, SangStat benefited from initial sales in the US and Europe of its PRA-STAT pre-transplant monitoring product, which is being distributed by Baxter through its affiliate Nextran, and also from the completion of a key milestone for development of CROSS-STAT, the next pre-transplant product to be sold by Baxter.</p><pre>T Cell Sciences Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months 0.94 2.20 (4.41) (2.15) Year 6.97 9.02 (11.58) (7.76) (ended Dec 31st)</pre><p>Excluding one-time relocation costs and losses on short-term investments, T Cell's 1994 net loss was about $8.2 million. The company says it has responded to the US FDA about questions raised in December regarding the 510(k) submission for its CD4 test kit, TRAx (see Clinica No 633, p 16).</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 155

{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}|{2360F67B-A7D7-4E2A-9C6C-5618FAE5CB5D}|{023AF810-44A6-4788-BF12-09F49F37E94F}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 28

US quarterly results roundup
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950227T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950227T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950227T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT051654
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 29

US quarterly results round-up
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 19

198600185,198601261
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

253423
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T183926Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

c4768d98-7ca3-42df-a810-8df70964df46
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T183926Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
